Brahms claims licensing first for prenatal marker:
This article was originally published in Clinica
Executive Summary
German firm Brahms says it has become the first company to license the use of the marker free beta human chorionic gonadotrophin (free betahCG) for prenatal diagnostics. The Hennigsdorf (Berlin) company has signed a licence agreement with JN Macri Technologies, an affiliate of NTD laboratories, New York. Free betahCG is one of several prenatal markers available on Brahms' fully automatic laboratory analyser, Kryptor. The licence agreement strengthens Brahms market position in this segment. Free betahCG is patented for application as a biomarker for assessing risk for foetal anomalies during early pregnancy. Brahms also provides immunoassays for other disease areas, including for the diagnosis of sepsis and infections, thyroid diseases, cancer and cardiac disease.